Verve Therapeutics Inc (VERV)
4.60
+0.05
(+1.10%)
USD |
NASDAQ |
Nov 21, 16:00
4.595
0.00 (0.00%)
After-Hours: 20:00
Verve Therapeutics Total Liabilities (Quarterly): 155.36M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 155.36M |
| June 30, 2024 | 154.82M |
| March 31, 2024 | 149.29M |
| December 31, 2023 | 153.19M |
| September 30, 2023 | 152.04M |
| June 30, 2023 | 123.91M |
| March 31, 2023 | 124.90M |
| December 31, 2022 | 128.29M |
| Date | Value |
|---|---|
| September 30, 2022 | 125.41M |
| June 30, 2022 | 27.93M |
| March 31, 2022 | 17.85M |
| December 31, 2021 | 26.77M |
| September 30, 2021 | 25.94M |
| June 30, 2021 | 21.12M |
| March 31, 2021 | 234.60M |
| December 31, 2020 | 142.32M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
17.85M
Minimum
Mar 2022
234.60M
Maximum
Mar 2021
110.23M
Average
126.85M
Median
Total Liabilities (Quarterly) Benchmarks
| Ardelyx Inc | 209.57M |
| Biomarin Pharmaceutical Inc | 1.438B |
| Sage Therapeutics Inc | 70.60M |
| ALX Oncology Holdings Inc | 48.91M |
| Immuneering Corp | 10.84M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 663.91M |
| Shareholders Equity (Quarterly) | 508.55M |
| Current Ratio | 13.05 |